射频消融联合化疗对比单纯化疗治疗局部晚期胰腺癌(PELICAN)随机对照试验研究方案
PELICAN试验是由荷兰胰腺癌研究组发起的国际多中心优效性随机对照试验,计划纳入228例局部晚期胰腺癌患者,在完成2个月系统治疗后疾病稳定或客观缓解且无法切除者随机接受射频消融联合化疗或单纯化疗,主要终点为总生存期。
要点
- 局部晚期胰腺癌经2个月FOLFIRINOX或(白蛋白紫杉醇/)吉西他滨治疗后未进展者方可随机。
- RFA联合化疗对比单纯化疗,主要终点为总生存期,计划在荷兰16家中心及欧洲其他4家中心纳入228例。
- 次要终点包括无进展生存期、RECIST缓解、CA19.9与CEA反应、毒性、生活质量、疼痛、费用及RFA免疫调节效应。
核心结论
- PELICAN试验旨在评估在2个月系统治疗后无疾病进展的局部晚期胰腺癌患者中,化疗联合RFA是否较单纯化疗改善总生存期。
研究设计与样本
- 国际多中心优效性随机对照试验,由荷兰胰腺癌研究组发起,计划在荷兰16家中心及欧洲其他4家中心共纳入228例患者。
- 符合DPCG标准的局部晚期胰腺癌患者,开始FOLFIRINOX或(白蛋白紫杉醇/)吉西他滨治疗后进行筛选。
- 完成4周期FOLFIRINOX或2周期(白蛋白紫杉醇/)吉西他滨(即2个月治疗)后重新分期,结果由全国在线专家小组评估。
- RECIST疾病稳定或客观缓解且无法切除的合格患者随机接受RFA后化疗或单纯化疗。
- 主要终点为总生存期;次要终点包括无进展生存期、RECIST缓解、CA19.9和CEA反应、毒性、生活质量、疼痛、费用及RFA免疫调节效应。
关键数值与推荐
- 约80%的局部晚期胰腺癌患者接受化疗,其中约10%接受切除术。
- 队列研究报告RFA在多模式治疗下总生存期可达26-34个月。
- 计划纳入228例患者。
临床怎么用
- 对于完成2个月系统治疗后疾病稳定或客观缓解且无法切除的局部晚期胰腺癌患者,可考虑纳入RFA联合化疗的临床研究。
局限性
- 目前缺乏研究RFA联合化疗用于局部晚期胰腺癌的随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 80% of patients with locally advanced pancreatic cancer (LAPC) are treated with chemotherapy, of whom approximately 10% undergo a resection. Cohort studies investigating local tumor ablation with radiofrequency ablation (RFA) have reported a promising overall survival of 26-34 months when given in a multimodal setting. However, randomized controlled trials (RCTs) investigating the effect of RFA in combination with chemotherapy in patients with LAPC are lacking. METHODS: The "Pancreatic Locally Advanced Unresectable Cancer Ablation" (PELICAN) trial is an international multicenter superiority RCT, initiated by the Dutch Pancreatic Cancer Group (DPCG). All patients with LAPC according to DPCG criteria, who start with FOLFIRINOX or (nab-paclitaxel/)gemcitabine, are screened for eligibility. Restaging is performed after completion of four cycles of FOLFIRINOX or two cycles of (nab-paclitaxel/)gemcitabine (i.e., 2 months of treatment), and the results are assessed within a nationwide online expert panel. Eligible patients with RECIST stable disease or objective response, in whom resection is not feasible, are randomized to RFA followed by chemotherapy or chemotherapy alone. In total, 228 patients will be included in 16 centers in The Netherlands and four other European centers. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, RECIST response, CA 19.9 and CEA response, toxicity, quality of life, pain, costs, and immunomodulatory effects of RFA. DISCUSSION: The PELICAN RCT aims to assess whether the combination of chemotherapy and RFA improves the overall survival when compared to chemotherapy alone, in patients with LAPC with no progression of disease following 2 months of systemic treatment. TRIAL REGISTRATION: Dutch Trial Registry NL4997 . Registered on December 29, 2015. ClinicalTrials.gov NCT03690323 . Retrospectively registered on October 1, 2018.
引用
- Walma MS, Rombouts SJ, Brada LJH, et al. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial. Trials. 2021. PMID: 33926539. doi:10.1186/s13063-021-05248-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。